Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Galera Therapeutics, Inc. (GRTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates"
08/10/2023 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Departure of Directors or Ce...
Docs: "Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese"
05/11/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/08/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates"
01/25/2023 8-K Other Events  Interactive Data
12/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis"
12/09/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
10/26/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
12/14/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Enrollment ongoing in GRECO-1 and GRECO-2 trials of rucosopasem in combination with SBRT in patients with NSCLC and Pancreatic Cancer; initial data from GRECO-1 expected in 1H2022 Strong cash position of $89M with expected cash runway into 2023 MALVERN, Pa. – November 10, 2021 – Galera Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2021 and provided recent..."
10/19/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis"
09/08/2021 8-K Quarterly results
08/18/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
06/17/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
04/28/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
01/06/2021 8-K Investor presentation
Docs: "Corporate Slide Presentation of Galera Therapeutics, Inc.",
"Corporate Slide Presentation of Galera Therapeutics, Inc."
11/10/2020 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : November 10, 2020 GALERA THERAPEUTICS, INC. Delaware 001-39114 46-1454898 2 W. Liberty Blvd #100 Malvern, PA 19355 725-1500 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exch...",
"Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates",
"Corporate Slide Presentation of Galera Therapeutics, Inc."
09/25/2020 8-K Quarterly results
09/16/2020 8-K Investor presentation
Docs: "Corporate Slide Presentation of Galera Therapeutics, Inc."
08/10/2020 8-K Quarterly results
07/14/2020 8-K Quarterly results
06/10/2020 8-K Submission of Matters to a Vote of Security Holders
Docs: "FORM 8-K"
05/12/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
05/12/2020 8-K Investor presentation, Quarterly results
Docs: "FORM 8-K",
"Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates",
"Corporate Slide Presentation of Galera Therapeutics, Inc. dated May 2020"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy